Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
ACS Nano ; 4(12): 7337-43, 2010 Dec 28.
Artigo em Inglês | MEDLINE | ID: mdl-21067154

RESUMO

Electrically conductive carbon nanotubes (CNTs) with high aspect ratios emit electrons at low electric fields, thus applications to large-area field emission (FE) devices with CNT cathodes are attractive to save energy consumption. However, the poor dispersion and easy bundling properties of CNTs in solvents have hindered this progress. We have solved these problems by growing single-walled CNTs (SWNTs) on single-walled carbon nanohorn (SWNH) aggregates that have spherical forms with ca. 100-nm diameters. In the obtained SWNT-SWNH hybrids (NTNHs), the SWNTs diameters were 1-1.7 nm and the bundle diameters became almost uniform, that is, less than 10 nm, since the SWNTs were separated by SWNH aggregates. We also confirmed that a large-area FE device with NTNH cathodes made by screen printing was highly and homogeneously bright, suggesting the success of the hybrid strategy.

2.
Gan To Kagaku Ryoho ; 31(7): 1083-5, 2004 Jul.
Artigo em Japonês | MEDLINE | ID: mdl-15272590

RESUMO

A 49-year old man underwent distal gastrectomy (D3) for circumferential type 3 cancer at the gastric antrum and cholecystectomy in September 2002. During the surgery, multiple metastases were observed predominantly in the left lobe of the liver, and lateral segmentectomy was performed as non-curative (curability-C) resection leaving the small metastases in the right lobe of the liver. Based on the results of chemo-sensitivity tests (5-FU 15.0%, CDDP 34.0%, MMC 35.3%, TXT 0.0%), we started to administer TS-1 (100 mg/day for 4 weeks followed by a 2-week rest interval) and MMC (10 mg/body on day 1). Due to leukocytopenia, the regimen was changed to TS-1 (100 mg/day for 4 weeks followed by a 2-week rest interval) and MMC (4 mg/body every other week [day 1, 14]) from the second course. Levels of tumor markers dropped and liver metastatic lesions remarkably decreased in size by CT after the third course. In conclusion, a combination of TS-1/MMC may be regarded as one option for postoperative adjuvant chemotherapy for outpatients.


Assuntos
Adenocarcinoma Papilar/tratamento farmacológico , Adenocarcinoma Papilar/secundário , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Neoplasias Gástricas/tratamento farmacológico , Adenocarcinoma Papilar/cirurgia , Administração Oral , Quimioterapia Adjuvante , Esquema de Medicação , Combinação de Medicamentos , Humanos , Injeções Intravenosas , Neoplasias Hepáticas/cirurgia , Masculino , Pessoa de Meia-Idade , Mitomicina/administração & dosagem , Ácido Oxônico/administração & dosagem , Piridinas/administração & dosagem , Neoplasias Gástricas/patologia , Neoplasias Gástricas/cirurgia , Tegafur/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA